Why Ocugen (OCGN) Stock May be A Good Buy On Every Fall

Ocugen Inc (NASDAQ: OCGN) has for years been a biopharmaceutical company that specializes in severe eye diseases, but in 2020 shareholders had to adapt to a change. This was due to the COVID-19 pandemic, which led Ocugen and other companies to change their business models and focus. For instance, Ocugen has worked with its partner Bharat Biotech to develop a coronavirus vaccine candidate called Covaxin.

Why Ocugen (OCGN) Stock May be A Good Buy On Every Fall

It is vital to keep in mind that Ocugen is not a vaccine company despite its partner Bharat making progress in the area. It is still committed to developing novel treatments for severe eye diseases. The stock has been on a bumpy ride. In December 2020, the stock traded at $0.3 before rising to its 52-week high of $18.77 in February. It later declined to a low of $5.24.

Related:  ADMA Biologics (ADMA) Pops 70% On 900 Thousand Shares

The stock is capable of big moves, and its next big move could be at any time. Covaxin has shown 78% efficacy against COVID-19 and could be a trigger for Ocugen. In the coming months, Ocugen is a stock to watch.

 

Richard McEntire

Finance and Entertainment Reporter Richard is a bottle of wine - the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.